NHO Revive to host Nebraska’s only prostate cancer Phase 3 trial

NHO Revive in Lincoln will be Nebraska’s only site for a Johnson & Johnson Phase 3 study testing pasritamig, a T-cell-based immune therapy for metastatic prostate cancer. The trial could expand options for patients whose disease has progressed after standard hormone treatments.

Why it matters: - The trial gives Nebraska patients access to a new prostate cancer treatment approach without leaving the state. - Pasritamig is designed to direct T-cells toward prostate cancer cells that express KLK2, which could help patients whose disease has kept growing after standard therapy. - The study could help define whether an immune-based combination improves outcomes over current treatment alone.

What happened: - NHO Revive said it will be Nebraska’s only site for Johnson & Johnson’s Phase 3 KLK2-PASenger prostate cancer trial. - The study is testing pasritamig plus docetaxel against docetaxel alone. - The announcement was dated July 22, 2026. - Dr. Kailash Mosalpura, medical oncologist at Nebraska Hematology-Oncology, said the trial brings innovative treatment options directly to patients in Lincoln.

The details: - The trial is a randomized, open-label study. - The primary goal is to see whether the combination extends the time patients live without their disease progressing on imaging scans. - Researchers will also measure overall survival, quality of life and other response outcomes. - Eligible participants must have histologically confirmed metastatic prostate adenocarcinoma. - Patients must have disease progression despite androgen deprivation therapy and at least one prior novel hormonal therapy. - Eligible patients must be 18 or older and have an ECOG performance status of 0 or 1. - Pasritamig targets cancer cells that express human kallikrein 2, or KLK2, a protein found on prostate cancer cells. - The drug is meant to work differently from chemotherapy and hormone-based therapies. - NHO Revive is a joint initiative between Nebraska Hematology Oncology and Revive Research Institute.

Between the lines: - The study reflects growing interest in immune therapies that try to attack prostate cancer more precisely than older drug classes. - Having the only Nebraska site may help NHO Revive attract patients who want access to a late-stage trial and a potential new option after standard care fails. - The partnership also positions Lincoln as a local access point for national oncology research.

What’s next: - Patients who meet the study criteria can seek enrollment through NHO Revive. - Researchers will track whether the pasritamig-docetaxel combination improves progression-free outcomes and other clinical measures. - The full announcement is available here.

The bottom line: - Nebraska patients now have local access to a Phase 3 prostate cancer trial that could help test a new immune-based treatment strategy.